A5033368647- Diabetes Treatment and Management
- Dialysis and Renal Disease Management
- Chronic Kidney Disease and Diabetes
- Lysosomal Storage Disorders Research
- Pancreatic function and diabetes
- Lipoproteins and Cardiovascular Health
- Diabetes Management and Research
- Metabolism, Diabetes, and Cancer
- Blood Pressure and Hypertension Studies
- Trypanosoma species research and implications
- Cardiovascular Function and Risk Factors
- Health Systems, Economic Evaluations, Quality of Life
- Renal Diseases and Glomerulopathies
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Heart Failure Treatment and Management
- Glycogen Storage Diseases and Myoclonus
- Erythropoietin and Anemia Treatment
- Neurological and metabolic disorders
- Parathyroid Disorders and Treatments
- Carbohydrate Chemistry and Synthesis
- Hormonal Regulation and Hypertension
- Acute Kidney Injury Research
- Metabolism and Genetic Disorders
- Diet and metabolism studies
- Biomedical Research and Pathophysiology
University of Würzburg
2016-2025
Universitätsklinikum Würzburg
2016-2025
Comprehensive Cancer Center Mainfranken
2012-2025
Klinik und Poliklinik für Kinder- und Jugendpsychiatrie
2011-2025
University of Oxford
2017-2024
Heidelberg University
1998-2024
University Hospital Heidelberg
1998-2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2022-2024
Center for Clinical Studies
2024
Social Neuroscience Lab
2005-2024
The effects of empagliflozin, an inhibitor sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality patients with type 2 diabetes at high risk are not known.We randomly assigned receive 10 mg or 25 empagliflozin placebo once daily. primary composite outcome was death from causes, nonfatal myocardial infarction, stroke, as analyzed the pooled group versus group. key secondary plus hospitalization for unstable angina.A total 7020 were treated...
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical...
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless presence or absence diabetes. More evidence is needed regarding effects these drugs across broad spectrum failure, including those with a markedly reduced ejection fraction.
Diabetes confers an increased risk of adverse cardiovascular and renal events. In the EMPA-REG OUTCOME trial, empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced major events in patients with type diabetes at high for We wanted to determine long-term effects analysis that was prespecified component secondary microvascular outcome trial.We randomly assigned estimated glomerular filtration rate least 30 ml per minute 1.73 m(2) body-surface area receive either empagliflozin (at...
Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, benefit statins such patients receiving hemodialysis, who are at high risk for disease and death, has not been examined.We conducted a multicenter, randomized, double-blind, prospective study 1255 subjects mellitus maintenance hemodialysis were randomly assigned to receive 20 mg atorvastatin per day or matching placebo. The primary end point was composite death from cardiac causes,...
Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici (Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luís Bronze (Portugal), John Chalmers (Australia), Tine De Backer (Belgium), Alejandro de la Sierra (Spain), Kyriakos Dimitriadis Dorota Drozdz (Poland), Béatrice Duly-Bouhanick (France), Brent M. Egan (USA), Serap Erdine Claudio Ferri (Italy), Slavomira Filipova (Slovak Republic), Anthony Heagerty (UK), Michael Hecht Olsen (Denmark), Dagmara Hering...
The effects of empagliflozin in patients with chronic kidney disease who are at risk for progression not well understood. EMPA-KIDNEY trial was designed to assess the treatment a broad range such patients.
The Kidney Disease: Improving Global Outcomes (KDIGO) 2020 Clinical Practice Guideline for Diabetes Management in Chronic Disease (CKD) represents the first KDIGO guideline on this subject. scope includes topics such as comprehensive care, glycemic monitoring and targets, lifestyle antihyperglycemic interventions, approaches to self-management optimal models of care. goal is generate a useful resource clinicians patients by providing actionable recommendations with infographics based...
Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but included limited numbers patients high risk and chronic kidney disease.To evaluate the effect linagliptin, a selective DPP-4 inhibitor, on outcomes in type at events.Randomized, placebo-controlled, multicenter noninferiority trial conducted from August 2013 to 2016 605 clinic sites 27 countries among adults diabetes, hemoglobin A1c...
Although inhibitors of the renin-angiotensin-aldosterone system can slow progression diabetic kidney disease, residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related 2 activators further reduce this unknown.We randomly assigned 2185 patients with type diabetes mellitus and stage 4 chronic disease (estimated glomerular filtration rate [GFR], 15 to <30 ml per minute 1.73 m(2) body-surface area) bardoxolone methyl, at a daily dose 20 mg, or placebo. The primary composite...
The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Disease (CKD) represents a focused update of the KDIGO 2020 guideline on topic. targets broad audience clinicians treating diabetes and CKD. Topic areas which recommendations are updated include: Chapter 1: Comprehensive care patients with CKD 4: Glucose-lowering therapies type 2 (T2D) Previous chapters Glycemic monitoring (Chapter 2), Lifestyle interventions 3),...
In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial involving 7,020 patients with type diabetes and established cardiovascular (CV) disease, empagliflozin given addition to standard of care reduced risk CV death by 38% versus placebo (hazard ratio [HR] 0.62 [95% CI 0.49, 0.77]). This exploratory mediation analysis assesses extent which treatment group differences covariates during contributed reduction...
Autosomal dominant polycystic kidney disease (ADPKD) is a slowly progressive hereditary disorder that usually leads to end-stage renal disease. Although the underlying gene mutations were identified several years ago, efficacious therapy curtail cyst growth and prevent failure not available. Experimental observational studies suggest mammalian target of rapamycin (mTOR) pathway plays critical role in growth.In this 2-year, double-blind trial, we randomly assigned 433 patients with ADPKD...